Saturday, November 15, 2014 11:06:11 AM
The float is shares that can be freely traded.
Authorized is shares that can be sold that is part of the treasury.
Outstanding are shares issued but can't be sold by the holders.
So we have no more treasury shares unless the stock has a reverse split then the treasury will be rebuilt but there will be a 50% increase in debt due noted as well as collateral required that can't be used for other forms of debt and be there is no collateral left then they can't reverse the stock. Now some may argue that capital surplus is an asset once released from its bonds with actual revenue some argue it is not an asset until this takes place and that it is nothing more then capital surplus " stored away capital until the date of release" that gives the meaning to growth stocks with exceptional earnings due to the capital surplus release do to depreciated assets accumulation.
If the debt can't be met before this market occurrence takes place then it falls into the hands of the debtor to put aside for its debt holder.
Now this depreciated asset that is now a debt can be sold to the public on a share reversal if given approval by the government who owes the debt should revenue be produced to unlock the capital that the government holds in surplus for the owners of the said depreciated assets.
If this should happen depending on market interest for the newly issued shares then and only then will the capital surplus be released by the Government agencies in authorization of the release of the depreciated assets.
If the old shares holders who own this debt not support the buying of the new debt owed by the government then there are slim chances the project can be finished were new revenue can unlock future capital for the company.
Get on board and support the company in releasing the new capital required to move this company forward into the future.
Recent PTIX News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 07:29:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/15/2023 08:50:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/29/2023 10:18:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2023 09:02:39 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/02/2023 08:29:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/13/2023 04:48:45 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 07:29:32 PM
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM